Research Project 2 Alzheimer's disease (AD) is the most common cause of dementia, affecfing about 5 million individuals in the US. Small noncoding RNAs, 21 to 30 nucleotides in length, including microRNAs (miRNAs), small interfering RNAs (siRNAs), repeat-associated small interfering RNAs, and piwi-associated RNAs, shape diverse cellular pathways. MiRNAs are sequence specific regulators of posttranscriptlonal gene expression and are believed to regulate the expression of thousands of target mRNAs, with each mRNA targeted by mulfiple miRNAs. Although it has been esfimated that miRNAs could regulate as many as one-third of human genes, highthroughput sequencing data indicate that only a portion of small RNAs in the genome have been discovered so far. Researchers have shown that the expression of RNA is altered in AD brains;however, a role for miRNAs in the pathogenesis of AD has not been established. We have established high-throughput expression profiling of miRNAs and small RNAs in the lab. Using the brain fissues of AD pafients from Emory ADRC Neuropathology Core, we have analyzed the expression of all known miRNAs and identified selective miRNAs are altered specifically in AD. In the proposed study, we plan to test the hypothesis that selective miRNA(s) that are aberrantly expressed in the brain tissues of AD patients modulate the pathogenesis of AD by post-transcriptionally regulating the expression of speciflc mRNAs that are involved in AD. Specifically, we plan to: 1) Identify and validate the altered expression of selective small RNAs in AD brain tissues;2) Identify the mRNA targets of the miRNAs aberrantly expressed in AD brain tissues;and 3) Determine whether the miRNAs aberranfiy expressed in AD brain fissues modulate AD pathogenesis in AD mouse model.

Public Health Relevance

Understanding of the role of small RNAs in AD will not only provide us insight into the molecular pathogenesis of AD, but also potentially provide new targets for further research and therapeutic development.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG025688-10
Application #
8662668
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4)
Project Start
Project End
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
10
Fiscal Year
2014
Total Cost
$165,560
Indirect Cost
$58,747
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Rangaraju, Srikant; Raza, Syed Ali; Li, Noel Xiang'An et al. (2018) Differential Phagocytic Properties of CD45low Microglia and CD45high Brain Mononuclear Phagocytes-Activation and Age-Related Effects. Front Immunol 9:405
Burke, Shanna L; Hu, Tianyan; Fava, Nicole M et al. (2018) Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. J Women Aging :1-25
Chalermpalanupap, Termpanit; Schroeder, Jason P; Rorabaugh, Jacki M et al. (2018) Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice. J Neurosci 38:74-92
Maezawa, Izumi; Nguyen, Hai M; Di Lucente, Jacopo et al. (2018) Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept. Brain 141:596-612
Bishof, Isaac; Dammer, Eric B; Duong, Duc M et al. (2018) RNA-binding proteins with basic-acidic dipeptide (BAD) domains self-assemble and aggregate in Alzheimer's disease. J Biol Chem 293:11047-11066
Peng, Katherine Y; Pérez-González, Rocío; Alldred, Melissa J et al. (2018) Apolipoprotein E4 genotype compromises brain exosome production. Brain :
Zhang, Qi; Ma, Cheng; Gearing, Marla et al. (2018) Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer's disease. Acta Neuropathol Commun 6:19
Gangishetti, Umesh; Christina Howell, J; Perrin, Richard J et al. (2018) Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimers Res Ther 10:98
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Umoh, Mfon E; Dammer, Eric B; Dai, Jingting et al. (2018) A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med 10:48-62

Showing the most recent 10 out of 444 publications